Terran Biosciences is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing a number of late-stage assets, which include novel psychedelic-based therapeutics.
In February 2023, they announced the publication of a PCT patent application covering novel prodrugs of psilocin, as well as the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA. These applications highlight new data from animal studies demonstrating that DMT and 5-MeO-DMT can be made orally active through Terran's proprietary prodrug approach. These compounds are considered to be among the most medically important psychedelic therapeutics, but due to extensive first pass metabolism in the liver, they are not active in oral form.